BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 16251181)

  • 1. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
    Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
    J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL.
    Moreno JL; Kaczmarek M; Keegan AD; Tondravi M
    Blood; 2003 Aug; 102(3):1078-86. PubMed ID: 12689929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
    Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
    J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
    Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
    J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
    Wittrant Y; Theoleyre S; Couillaud S; Dunstan C; Heymann D; Rédini F
    Exp Cell Res; 2004 Feb; 293(2):292-301. PubMed ID: 14729467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF; Lie A; Ransjö M
    J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones.
    Schwab AM; Granholm S; Persson E; Wilkes B; Lerner UH; Conaway HH
    Endocrinology; 2005 Oct; 146(10):4349-61. PubMed ID: 15994344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-to-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption.
    Okada Y; Morimoto I; Ura K; Watanabe K; Eto S; Kumegawa M; Raisz L; Pilbeam C; Tanaka Y
    Endocr J; 2002 Aug; 49(4):483-95. PubMed ID: 12402981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells.
    Hasegawa T; Yoshimura Y; Kikuiri T; Yawaka Y; Takeyama S; Matsumoto A; Oguchi H; Shirakawa T
    J Periodontal Res; 2002 Dec; 37(6):405-11. PubMed ID: 12472833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.